Compliance & Governance
Governed by Design. Compliant by Architecture. Independent by Principle.
RDDT's compliance framework is not a layer added on top of its technology. It is the foundation on which the entire operating model is built. Every data flow, clinical process, and economic relationship is structured to protect patients, preserve physician independence, and maintain the separation between biopharmaceutical sponsorship and clinical decision-making.
Compliance is not a feature. It is the architecture.
Contact UsRDDT provides U.S. healthcare organizations with Rare Disease Patient Analytic Services, which combine compliant patient-first funding, proprietary analytics, independent clinical review, and patient-consented, physician-directed evaluation to create new, sustainable revenue for healthcare organizations while advancing earlier recognition and diagnosis of previously unsuspected rare disease patients for whom potentially life-saving FDA-approved therapies already exist, within their existing healthcare systems.
Independence by Design
The Neutral Intermediary
RDDT operates independently of healthcare organizations and biopharmaceutical manufacturers. Neither sector owns or controls RDDT, nor does RDDT hold ownership interests in either. Our independence is structural, clinical, and economic.
BioPharma funds defined services at fair market value, independent of patient outcomes. RDDT has no financial interest in testing, treatment, prescribing, referrals, enrollment, or any predetermined diagnosis. Healthcare organizations and their physicians retain complete clinical authority.
This neutrality enables RDDT to deliver comprehensive, unbiased clinical dossiers based on relevant available evidence, without favoring any manufacturer, therapy, or predetermined conclusion.
Our independence protects the patient, preserves physician judgment, and makes compliant collaboration between healthcare and biopharma possible.
Neutral by design
Structural. Clinical. Economic.
Independence is not simply a policy. It is built into how RDDT is organized, funded, and governed.
Institutional Control of Patient Data
Healthcare organizations retain authority over patient identity, data permissions, and clinical governance.
Independent Clinical Judgment
Qualified clinical experts independently evaluate analytical findings, while treating physicians retain authority over patient evaluation, diagnosis, and treatment.
Outcome-Independent Economics
Biopharmaceutical sponsorship funds authorized analytical services through a fair-market-value framework, independent of diagnostic findings or treatment decisions.
Neutral Intermediary Governance
RDDT maintains separation between commercial sponsors and clinical decision-making, protecting physician independence and patient choice.
Analytical Quality & Accountability
RDDT applies proprietary disease-specific methodologies and independent clinical review to deliver high-confidence suspect cohorts for further clinical consideration.
Data Use
Health System Data. Governed by Design.
RDDT performs authorized, disease-specific analysis of appropriately de-identified clinical information within a secure, governed environment.
Analytical findings undergo independent clinical expert review before being returned to participating healthcare organizations for physician-directed evaluation.
Healthcare organizations retain control of patient identity, re-identification, and clinical decisions. RDDT's use of participating health system data is limited to the purposes authorized under the governing agreements.
Patient-level health system datasets are not used to train RDDT's proprietary methodologies.
Compliant Sponsorship
Built for Compliance. Designed for Patient Benefit.
A Good-Faith Investment in Patients, Without Promised Commercial Outcomes.
RDDT provides biopharmaceutical manufacturers with a compliant, independently governed pathway to support surfacing previously unsuspected rare disease patients within existing healthcare populations for independent clinical evaluation.
Our operating model rests on five foundational principles, outlined above:
Good-Faith Investment in Patient Visibility
Biopharmaceutical sponsorship supports the legitimate clinical objective of bringing previously unrecognized rare disease patterns to the attention of qualified healthcare professionals, with the patient as the intended primary beneficiary.
No Promised Diagnostic Outcomes
RDDT does not guarantee that any patient will receive a particular diagnosis. Analytical findings are subject to independent clinical evaluation, and every clinical hypothesis may be confirmed, ruled out, or rejected.
No Promised Treatment Utilization
Sponsorship carries no commitment that any patient will receive, be prescribed, or utilize a manufacturer's therapy. All treatment decisions remain exclusively with independent treating physicians and their patients.
No Quid Pro Quo
Sponsor payments are not conditioned on referrals, prescriptions, treatment selection, product utilization, or other commercial outcomes. Sponsors do not direct patient-level clinical decisions.
Upfront, Population-Based Economics
Initial analytical services are funded through predetermined, fair-market-value fees based on the authorized population searched, with bulk search payments made upfront under the applicable agreement. Any separately contracted Clinical Evaluation & Reconciliation Services are governed by defined deliverables and are not contingent on diagnosis, prescribing, or treatment utilization.
BioPharma funds the opportunity for patients to become visible. Independent healthcare professionals determine what happens next.
A Neutral Intermediary. A Patient-First Responsibility.
RDDT operates as an independent, neutral intermediary between healthcare organizations and biopharmaceutical sponsors, aligning their interests around a single purpose: improving the opportunity for earlier recognition and diagnosis of patients living with rare diseases.
Our neutrality is deliberate. Sponsors fund defined services at fair market value, independent of patient outcomes, and do not direct patient selection, clinical evaluation, diagnosis, or treatment. RDDT has no financial interest in testing, prescribing, referrals, or treatment decisions. Healthcare organizations retain control of patient identity and clinical governance, while physicians maintain complete independence over patient care.
But neutrality does not mean indifference to outcomes.
RDDT has a responsibility to measure the performance of its methodologies, evaluate documented clinical findings and, where expressly authorized, use validated performance insights to refine future analytical precision. Our Clinical Findings & Performance Validation process makes that responsibility measurable and accountable.
We remain neutral in clinical and commercial decision-making, but unwavering in our responsibility to patients.
Clinical Findings & Performance Validation
A Responsibility to Validate. An Obligation to Improve.
RDDT believes that surfacing a previously unsuspected rare disease patient carries a responsibility beyond the initial analytical finding. That responsibility includes understanding what subsequent independent clinical evaluation reveals and applying those learnings to improve the opportunity for earlier recognition of future patients.
Through its governed Clinical Findings & Performance Validation process, participating healthcare organizations document and report clinical dispositions, including confirmations, rule-outs, disagreements, and inconclusive findings. These findings provide essential evidence for measuring analytical performance, understanding where methodologies succeed or fall short, and guiding their refinement.
RDDT has an obligation to learn from these clinical findings and, within established contractual permissions and privacy safeguards, incorporate those learnings into the continuous validation and improvement of its proprietary methodologies.
This process preserves healthcare organization control of patient information and the independence of every clinical decision. RDDT surfaces clinical suspicions; independent experts evaluate the evidence; physicians determine diagnosis and care.
Evidence-based analytics. Independently validated findings. Greater opportunity for the patients still waiting to be recognized.
Quality, Security & Responsible Technology Governance
Supported by Documented Quality, Security, and Governance Practices.
RDDT's technology and operating model are supported by established quality management standards, independent security assessments, healthcare privacy safeguards, and responsible AI governance. These disciplines are fundamental to protecting patient information, maintaining institutional trust, and supporting secure, scalable collaboration with healthcare organizations.
Quality Management
Internationally recognized standards for consistent processes, operational quality, and continuous improvement.
Security & Operational Controls
Independent assessment of security controls and their operating effectiveness over a defined review period.
Healthcare Privacy & Security
Privacy and security safeguards designed to protect healthcare information and support applicable regulatory and contractual obligations.
Healthcare Compliance Expertise
Professional healthcare compliance expertise supporting regulatory awareness, ethical operations, and institutional accountability.
Responsible AI Management
International framework for governing artificial intelligence through structured risk management, accountability, oversight, and continuous improvement.